KalVista raises ~$58M in registered direct offering of 9.48M shares at $6.00/share plus warrants

KalVista Pharmaceuticals, Inc.

9,484,199 shares at $6.00 per share, plus pre-funded warrants for 182,470 shares at $5.999 each.
Net proceeds expected ~$58M for clinical trials, commercial development, R&D, and working capital.
Offering closes Dec 28, 2022; post-closing shares outstanding ~34.1M (dilution of ~9.7M shares).
No underwriter; securities offered under existing shelf registration (File No. 333-256378).

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

KalVista Pharmaceuticals, Inc. entered into Subscription Agreements with certain purchasers valued at approximately $58 million (effective 2022-12-23).

Action: entry
Agreement: equity purchase
Counterparty: certain purchasers
Value: approximately $58 million
Effective: 2022-12-23

Exact text from the filing

On December 23, 2022, KalVista Pharmaceuticals, Inc. (the “Company”) entered into a subscription agreement (collectively, the “Subscription Agreements”) with certain purchasers, pursuant to which the Company agreed to issue and sell in a registered direct offering (the “Offering”) (i) an aggregate of 9,484,199 shares (the “Shares”) of the Company’s common stock, $0.001 par value per share (“Common Stock”) and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 182,470 shares of Common Stock.

View on SEC.gov

Browse all material agreements →

KalVista Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-312030

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.